Search Results - "Sivamurthy, Krupa"

Featured Cover by Miesbach, Wolfgang, von Drygalski, Annette, Smith, Clive, Sivamurthy, Krupa, Pinachyan, Karen, Bensen‐Kennedy, Debbie, Drelich, Douglass, Kulkarni, Roshni

“…The cover image is based on the Review The current challenges faced by people with hemophilia B by Wolfgang Miesbach et al., https://doi.org/10.1111/ejh.14135…”
Get full text

A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis by Dampier, Carlton D., Telen, Marilyn Jo, Wun, Ted, Brown, R. Clark, Desai, Payal, El Rassi, Fuad, Fuh, Beng, Kanter, Julie, Pastore, Yves, Rothman, Jennifer, Taylor, James G., Readett, David, Sivamurthy, Krupa M., Tammara, Brinda, Tseng, Li-Jung, Lozier, Jay Nelson, Thackray, Helen, Magnani, John L., Hassell, Kathryn L.

“…•Rivipansel was safe and well-tolerated in sickle cell patients hospitalized for VOC, but did not meet primary or secondary end points.•Rivipansel use early in…”
Get full text

The current challenges faced by people with hemophilia B by Miesbach, Wolfgang, Drygalski, Annette, Smith, Clive, Sivamurthy, Krupa, Pinachyan, Karen, Bensen‐Kennedy, Debbie, Drelich, Douglass, Kulkarni, Roshni

“…Hemophilia B (HB) is a rare, hereditary disease caused by a defect in the gene encoding factor IX (FIX) and leads to varying degrees of coagulation deficiency…”
Get full text

PERIPHERAL ARTERIAL TONOMETRY IN ASSESSING ENDOTHELIAL DYSFUNCTION IN PEDIATRIC SICKLE CELL DISEASE by Sivamurthy, Krupa M., Dampier, Carlton, MacDermott, MaryLou, Maureen, Meier, Cahill, Michele, Hsu, Lewis L.

“…Background: SCD is characterized by hemolysis and oxidative stress, resulting in endothelial dysfunction (EDF). Peripheral arterial tonometry (PAT), a…”
Get full text

Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B by Shah, Jinesh, Kim, Hongseok, Sivamurthy, Krupa, Monahan, Paul E., Fries, Michael

“…Hemophilia B is a rare bleeding condition where blood does not clot properly, causing excessive bleeding. It is caused by a change or mutation to a gene,…”
Get full text

Durability of Factor IX Activity and Bleeding Rate in People with Severe or Moderately Severe Hemophilia B after 5 Years of Follow-up in the Phase 1/2 Study of AMT-060, and after 3 Years of Follow-up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061) by Miesbach, Wolfgang A., Recht, Michael, Key, Nigel S., Sivamurthy, Krupa, Monahan, Paul E., Pipe, Steven W.

Get full text

Assessing health plan payer’s budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States by Wilson, Michele, McDade, Cheryl, Thiruvillakkat, Kris, Rouse, Robert, Sivamurthy, Krupa, Yan, Songkai

“…This study assessed the budget impact of introducing etranacogene dezaparvovec to a hypothetical US health plan formulary for people with severe or moderately…”
Get full text

A New Measure Assessing Recovery from a Sickle Cell Crisis by Vendetti, Nicholas J., Benjamin, Katy, Moshkovich, Olga, Lipman, Kelly, Sivamurthy, Krupa M., Pleil, Andreas M.

“…Rationale: Vaso-occlusive crisis (VOC) is a recurring complication of sickle cell disease (SCD) and a common reason for emergency department visits and…”
Get full text

Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients by Charnigo, Robert J, Tan, Beesan, Rybin, Denis, Pittman, Debra D, Sivamurthy, Krupa M., Beidler, David, Clarke, Nicholas

“…▪ Background: Current treatment options (eg, hydroxyurea, chronic blood infusions, and bone marrow or stem cell transplantation) for the prevention of sickle…”
Get full text

Factors that influence the bleeding phenotype in severe hemophilic patients by Rendo, Pablo, Shafer, Frank, Korth-Bradley, Joan M., Sivamurthy, Krupa, Korin, Jorge

“…Hemophilia A and B are rare, X-linked bleeding disorders resulting from a partial or total deficiency of functionally active coagulation factor VIII or factor…”
Get full text

Health Outcomes in Vaso Occlusive Crisis of Sickle Cell Disease - Retrospective Indicators by Rajpura, Jigar, Shafer, Frank E., Sivamurthy, Krupa M., Kollmer, Carl, Vendetti, Nicholas

“…Abstract 4699 Retrospective data analysis is relatively inexpensive & allows evaluation of rare conditions such as Vaso Occlusive Crisis (VOC) of Sickle Cell…”
Get full text

Identification and Characterization of Clinical, Humanistic and Economic Outcomes and Clinical Endpoints in Vaso Occlusive Crisis of Sickle Cell Disease – A Systematic Review by Rajpura, Jigar, Thomas, Joseph, Shafer, Frank E., Sivamurthy, Krupa M., Kollmer, Carl, Vendetti, Nicholas

“…Abstract 4710 Health outcomes often serve as a measure of treatment efficacy in clinical studies. Although self-reported, observational, & clinical techniques…”
Get full text

Assessing Endothelial Dysfunction in Pediatric Sickle Cell Disease by Sivamurthy, Krupa, Dampier, Carlton, MacDermott, MaryLou, Meier, Maureen, Cahill, Michele, Hsu, Lewis L.

“…Background: There has been growing interest in the vasculopathy occurring in sickle cell disease (SCD), which includes blunted nitric oxide (NO) responsiveness…”
Get full text